Tolerability and Safety of the New Anti-Obesity Medications

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F14%3A43908712" target="_blank" >RIV/00216208:11120/14:43908712 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023761:_____/14:#0000454

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s40264-014-0206-3" target="_blank" >http://dx.doi.org/10.1007/s40264-014-0206-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40264-014-0206-3" target="_blank" >10.1007/s40264-014-0206-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Tolerability and Safety of the New Anti-Obesity Medications

Popis výsledku v původním jazyce

Worldwide obesity prevalence has nearly doubled since 1980. Due to numerous co-morbidities, obesity represents a serious health and socioeconomic problem worldwide. Pharmacotherapy should be an integral part of comprehensive obesity management. Drug therapy can assist in weight loss and its maintenance in those individuals who do not achieve appropriate weight loss through lifestyle interventions alone. After the withdrawal of sibutramine from the market in 2010, orlistat, a lipase inhibitor, was the only remaining prescription drug approved for the long-term treatment of obesity. In 2012, phentermine/topiramate extended-release (PHEN/TPM ER) combination and lorcaserin were approved by the US FDA as novel medications for long-term weight management. Three major phase III trials conducted with each drug confirmed their efficacy in terms of weight loss/maintenance and improvement of cardiometabolic risks. No head-to-head studies between the two new anti-obesity drugs have been carried ou

Název v anglickém jazyce

Tolerability and Safety of the New Anti-Obesity Medications

Popis výsledku anglicky

Worldwide obesity prevalence has nearly doubled since 1980. Due to numerous co-morbidities, obesity represents a serious health and socioeconomic problem worldwide. Pharmacotherapy should be an integral part of comprehensive obesity management. Drug therapy can assist in weight loss and its maintenance in those individuals who do not achieve appropriate weight loss through lifestyle interventions alone. After the withdrawal of sibutramine from the market in 2010, orlistat, a lipase inhibitor, was the only remaining prescription drug approved for the long-term treatment of obesity. In 2012, phentermine/topiramate extended-release (PHEN/TPM ER) combination and lorcaserin were approved by the US FDA as novel medications for long-term weight management. Three major phase III trials conducted with each drug confirmed their efficacy in terms of weight loss/maintenance and improvement of cardiometabolic risks. No head-to-head studies between the two new anti-obesity drugs have been carried ou

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Drug Safety

ISSN

0114-5916

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

10

Strana od-do

693-702

Kód UT WoS článku

000344615000004

EID výsledku v databázi Scopus

—